K Number
K162603
Manufacturer
Date Cleared
2017-05-26

(249 days)

Product Code
Regulation Number
870.2700
Reference & Predicate Devices
Predicate For
N/A
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
Intended Use

The noninvasive Masimo O3 Regional Oximeter System and accessories are intended for use as an adjunct monitor of absolute and trended regional hemoglobin oxygen saturation of blood (rSO2) in the cerebral region under the sensors. The Masimo O3 Regional Oximeter System and accessories are indicated for use on adults ≥ 40 kg and on pediatrics > 5 kg and < 40 kg in healthcare environments.

Device Description

The Masimo Regional Oximetry System (O3 System) includes the O3 Sensors and the O3 Module. The O3 System measures hemoglobin under the sensor, allowing clinicians to continuously and accurately determine the absolute and trend measurements of regional blood oxygenation saturation in the tissue (rSO2). The O3 Sensors includes optical components that collect physiological signals. The O3 Module includes Masimo technology for processing those signals which resulted in regional oximetry (rSO2) measurements. In turn, these measurements are displayed on the Host/Backboard device.

The O3 Sensor is a single-patient use adhesive sensor and is supplied non-sterile. The O3 Sensor, comprising of an emitter and two detectors, is applied to the patient's forehead at one end. The other end of the sensor is connected to a patient cable which in turn is connected to the 03 Module. Up to two 03 Sensors can be connected to each 03 Module and both sensors can be connected to a patient.

The O3 Module includes Near InfraRed Spectroscopy (NIRS) technology. The O3 Sensor uses multiple wavelengths in the range of near infrared wavelengths to measure light absorption in the tissue. The O3 Sensors and O3 Module make up the O3 System for the monitoring of absolute regional hemoglobin oxygen saturation of blood (rSO2) under the sensors. The O3 System does not have its own power. The O3 Module is powered by connecting to a Host/Backboard Device such as the Root Monitoring System (Root in turn is powered by either AC power or internal rechargeable batteries.

The O3 System provides the following key measurements:

  • Regional Oxygenation (rSO2): Regional tissue oxygenation level in the deep tissue local to the sensor site, including cerebral tissue
  • Delta Baseline (Abase): Relative difference in rSO2 with respect to baseline rSO2
  • Area Under the Limit (AUL index): Index that quantifies the duration (amount of time the patient stays below rSO2 low alarm limit) and depth (refers to the gap between the patient's rSO2 level and the rSO2 low alarm limit) of patient's stay below the user-defined rSO2 low alarm limit (LAL)
  • Delta SpO2 (ΔSpO2): The difference between SpO2 and rSO2. The source of SpO2 is from peripheral SpO2 measurement (using pulse oximeter).
AI/ML Overview

The provided document describes the Masimo O3 Regional Oximeter System, specifically focusing on the O3 Pediatric Sensor, and its equivalence to predicate devices (K160526 and K082327). The document outlines non-clinical and clinical testing performed to demonstrate substantial equivalence.

Here's an analysis of the acceptance criteria and the study proving the device meets them:

1. A table of acceptance criteria and the reported device performance

The acceptance criteria for accuracy are presented as ARMS (Accuracy Root Mean Square) values.

FeatureAcceptance Criteria (Specification)Reported Device Performance (O3 Pediatric Sensor)
rSO2 Measurement Accuracy
Adults ≥ 40kg (using O3 Large Sensor - Predicate)Absolute ARMS, 4% for SavO2 of 45%-85%N/A (this is predicate performance)
Trending ARMS, 3% for SavO2 of 45%-85%N/A (this is predicate performance)
Pediatrics ≥ 5 kg and < 40 kg (O3 Pediatric Sensor)Absolute ARMS, 5% for SavO2 of 45%-85%5% for SavO2 of 45%-85%
Trending ARMS, 3% for SavO2 of 45%-85%3% for SavO2 of 45%-85%

(Emphasis added to highlight the performance of the device under review, the O3 Pediatric Sensor)

2. Sample size used for the test set and the data provenance

  • Sample Size for Absolute ARMS (Pediatric): 33 male and female pediatric patients.
  • Sample Size for Trending ARMS (Pediatric): Not explicitly stated as a distinct number of patients. The trending study used the O3 Large Sensor as a reference and collected rSO2 data from both the O3 Large Sensor and O3 Pediatric Sensor. It's implied this was performed on a subset or all of the 33 pediatric patients, but the exact number for the trending analysis isn't isolated.
  • Data Provenance: The document does not explicitly state the country of origin. It indicates the study involved "pediatric patients," suggesting human clinical data. It is a prospective study, as blood draws were taken "before and after his/her medical procedure" for the absolute ARMS, and trending data was collected.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts

The ground truth for the rSO2 measurements was established by "blood draws (arterial and jugular blood)" which were then analyzed to determine blood oxygen saturation. This is a direct physiological measurement, considered objective, and does not involve human expert interpretation in the same way imaging studies might. Therefore, the concept of "number of experts" with specific qualifications for ground truth establishment (like radiologists) is not applicable here. The accuracy is against a direct physiological laboratory standard, not an expert consensus.

4. Adjudication method (e.g., 2+1, 3+1, none) for the test set

Since the ground truth for both absolute and trending accuracy was based on direct blood measurements (physiological reference), there was no adjudication method involving human experts for the test set.

5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

No MRMC comparative effectiveness study was done. This device is an oximeter, which provides a direct measurement (rSO2) rather than an interpretation that would be assisted by AI. The document describes a comparison of the device (O3 Pediatric Sensor) against a physiological reference and against another sensor (O3 Large Sensor for trending), not human reader performance with or without AI assistance.

6. If a standalone (i.e., algorithm only without human-in-the-loop performance) was done

Yes, the primary performance evaluation for accuracy (Absolute ARMS and Trending ARMS) is a standalone (algorithm only) performance evaluation. The device provides the rSO2 measurements directly, based on its NIRS technology and signal processing. The accuracy is reported for the device's measurements compared to a reference standard (blood draws or another sensor). While a human user reads the display, the accuracy itself is of the device's output.

7. The type of ground truth used (expert consensus, pathology, outcomes data, etc.)

The ground truth used was physiological measurements (blood draws) for absolute accuracy. Specifically, "Blood draws (arterial and jugular blood) were taken for each subject." For trending accuracy, the O3 Large Sensor's measurements (which were previously established via blood reference) served as the comparative ground truth.

8. The sample size for the training set

The document does not specify a separate training set sample size. This is typical for a device submission that primarily focuses on hardware and embedded algorithms, where the "training" (calibration and algorithm development) often occurs internally during the device development phase, and the submission focuses on the validation or test data. The "Clinical Testing" section describes the validation study for the new O3 Pediatric Sensor.

9. How the ground truth for the training set was established
As the document does not explicitly mention a separate "training set," it does not describe how ground truth for such a set was established. It describes the ground truth for the clinical validation (test) set, which was established through blood draws (arterial and jugular blood), considered the reference standard for blood oxygen saturation. It's reasonable to infer that the underlying scientific principles and initial calibrations would have relied on similar, well-established physiological measurement techniques.

{0}------------------------------------------------

Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo consists of a stylized graphic of three human profiles facing right, overlaid and slightly offset from each other. Above the graphic, the text "HEALTH & HUMAN SERVICES • USA" is arranged in a circular fashion, indicating the department's name and country.

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

May 26, 2017

Masimo Corporation Marguerite Thomlinson Sr. Director, Regulatory Affairs 52 Discovery Irvine, California 92618

Re: K162603

Trade/Device Name: Masimo O3 Regional Oximeter System Regulation Number: 21 CFR 870.2700 Regulation Name: Oximeter Regulatory Class: Class II Product Code: MUD Dated: April 25, 2017 Received: April 26, 2017

Dear Marguerite Thomlinson:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices. good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical devicerelated adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

{1}------------------------------------------------

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely,

William J. Heetderks -S 2017.05.26 11:06:05 -04'00'

Carlos L. Peña, Ph.D., M.S. for Director Division of Neurological and Physical Medicine Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

Indications for Use

510(k) Number (if known) K162603

Device Name

Masimo O3 Regional Oximeter System

Indications for Use (Describe)

The noninvasive Masimo O3 Regional Oximeter System and accessories are intended for use as an adjunct monitor of absolute and trended regional hemoglobin oxygen saturation of blood (rSO2) in the cerebral region under the sensors. The Masimo O3 Regional Oximeter System and accessories are indicated for use on adults ≥ 40 kg and on pediatrics > 5 kg and < 40 kg in healthcare environments.

Type of Use (Select one or both, as applicable)

Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

Image /page/3/Picture/0 description: The image shows the logo for Masimo Corporation. The logo consists of a red circle with a white line running through it, followed by the word "Masimo" in black, bold letters. To the right of the word "Masimo" are the words "MASIMO CORPORATION" in gray, followed by the address "52 Discovery, Irvine, CA 92618" also in gray.

Submitter and Address ofManufacturing Facility:Masimo Corporation52 DiscoveryIrvine, CA 92618Phone: (949) 297-7683FAX: (949) 297-7592
Date:May 10, 2017
Contact:Marguerite ThomlinsonSenior Director, Regulatory Affairs
Trade Name:Masimo O3 Regional Oximeter System
Common Name:Oximeter, Tissue Saturation
Classification Regulation/Product Code:21 CFR 870.2700, Class II/MUD
Establishment RegistrationNumber:2031172
Reason for PremarketNotification:New Device - Masimo O3 Pediatric Sensor
Predicate Device:K160526 – Masimo O3 Regional Oximeter SystemK082327- Invos 5100C with Pediatric SomaSensor
Performance StandardsNo performance standards for the above device have beenpromulgated pursuant to Section 514.

Device Description

The Masimo Regional Oximetry System (O3 System) includes the O3 Sensors and the O3 Module. The O3 System measures hemoglobin under the sensor, allowing clinicians to continuously and accurately determine the absolute and trend measurements of regional blood oxygenation saturation in the tissue (rSO2). The O3 Sensors includes optical components that collect physiological signals. The O3 Module includes Masimo technology for processing those signals which resulted in regional oximetry (rSO2) measurements. In turn, these measurements are displayed on the Host/Backboard device.

The O3 Sensor is a single-patient use adhesive sensor and is supplied non-sterile. The O3 Sensor, comprising of an emitter and two detectors, is applied to the patient's forehead at one end. The other end of the sensor is connected to a patient cable which in turn is connected to

{4}------------------------------------------------

Image /page/4/Picture/0 description: The image shows the logo for Masimo Corporation. The logo consists of a red circle with a white checkmark inside, followed by the word "Masimo" in black, bold letters. To the right of the company name is the text "Masimo Corporation" and the address "52 Discovery, Irvine, CA 92618" in a smaller, gray font.

the 03 Module. Up to two 03 Sensors can be connected to each 03 Module and both sensors can be connected to a patient.

The O3 Module includes Near InfraRed Spectroscopy (NIRS) technology. The O3 Sensor uses multiple wavelengths in the range of near infrared wavelengths to measure light absorption in the tissue. The O3 Sensors and O3 Module make up the O3 System for the monitoring of absolute regional hemoglobin oxygen saturation of blood (rSO2) under the sensors. The O3 System does not have its own power. The O3 Module is powered by connecting to a Host/Backboard Device such as the Root Monitoring System (Root in turn is powered by either AC power or internal rechargeable batteries.

The O3 System provides the following key measurements:

  • Regional Oxygenation (rSO2): Regional tissue oxygenation level in the deep tissue ● local to the sensor site, including cerebral tissue
  • Delta Baseline (Abase): Relative difference in rSO2 with respect to baseline rSO2 ●
  • Area Under the Limit (AUL index): Index that quantifies the duration (amount of time the patient stays below rSO2 low alarm limit) and depth (refers to the gap between the patient's rSO2 level and the rSO2 low alarm limit) of patient's stay below the user-defined rSO2 low alarm limit (LAL)
  • Delta SpO2 (ΔSpO2): The difference between SpO2 and rSO2. The source of SpO2 . is from peripheral SpO2 measurement (using pulse oximeter).
O3 System Specifications
FEATURESPECIFICATION
Display
Display RangeRegional Oxygen Saturation (rSO2): 0-99%Δbase: 0-99%(Δbase is the difference between regional and baseline rSO2)
Display Resolution for MeasurementsrSO2: 1%Δbase: 1%
rSO2 Measurement Accuracy, Adults ≥ 40kgAbsolute ARMS, 4% for SavO2 of 45%-85%Trending ARMS, 3% for SavO2 of 45%-85%
SO2 Measurement Accuracy,Pediatrics ≥ 5 kg and < 40 kgAbsolute ARMS, 5% for SavO2 of 45%-85%Trending ARMS, 3% for SavO2 of 45%-85%
General
Visual/audible alarmHost/backboard device (Root per K140188, K151644 andK153225) is IEC60601-1-8 compliant
Storage/recordingHost/backboard device (Root per K140188, K151644 andK153225) trend/data storage

See the table below for the O3 System specifications.

{5}------------------------------------------------

Image /page/5/Picture/0 description: The image shows the logo for Masimo Corporation. The logo consists of a red circle with a white line running through it, followed by the word "Masimo" in black, bold letters. To the right of the word "Masimo" is the text "MASIMO CORPORATION" in gray, followed by the address "52 Discovery, Irvine, CA 92618" also in gray.

O3 System Specifications
FEATURESPECIFICATION
Electrical
AC Power orBattery, RechargeableInterfaceHost/backboard device (Root per K140188, K151644 andK153225) provides power to O3 System
O3 Module ConnectionMOC-9 interface with host/backboard device (Root perK140188, K151644 and K153225)
Mechanical
O3 Module: Dimensions/Weight5x1.8x0.6 inch/ 7 oz
O3 Large Sensor: Dimensions/Weight2.9x1.5x0.1 inch/0.20 oz.
O3 Pediatric Sensor: Dimensions/Weight2.6x1.1x0.1 inch/0.18 oz.
Environmental
O3 Module
• Operating Temperature0°C to +40°C, ambient humidity
• Storage Temperature-40°C to +70°C, ambient humidity
• Operating/ Storage Humidity10% to 95%, non-condensing
• AltitudeUp to 12,000 feet (3700 meters)
O3 Large Sensor and O3 Pediatric Sensor
• Operating Temperature+5°C to +40°C
• Storage Temperature-40°C to +60°C
• Humidity15% to 90% relative humidity

Intended Use

The O3 System, consisting of the O3 Sensors and O3 Module, is intended for noninvasive monitoring of absolute regional oxygen saturation. The computed saturation values are displayed on a host/backboard monitor such as the Masimo Root System (K140188, K151644 and K153225). The O3 System is intended to be used in healthcare environments.

Indications For Use

The noninvasive Masimo O3 Regional Oximeter System and accessories are intended for use as an adjunct monitor of absolute and trended regional hemoglobin oxygen saturation of blood (rSO2) in the cerebral region under the sensors. The Masimo O3 Regional Oximeter System and accessories are indicated for use on adults ≥ 40 kg and on pediatrics > 5 kg and < 40 kg in healthcare environments.

{6}------------------------------------------------

Image /page/6/Picture/0 description: The image shows the Masimo Corporation logo. The logo consists of a red circle with a white checkmark inside, followed by the word "Masimo" in black, bold letters. To the right of the logo is the text "MASIMO CORPORATION" in gray, followed by the address "52 Discovery, Irvine, CA 92618" also in gray.

Technological Characteristics

Principle of Operation

The O3 System's operating principle is based on multi-distance diffuse reflectance spectroscopy. The O3 System use light to examine a cross-section tissue microvasculature (a mixed bed of arterioles, capillaries and venules) and analyzes the light returned after having passed through the tissues. The spectroscopic analysis determines concentrations of hemoglobin in its oxygenated and deoxygenated states.

Mechanism of Action for Achieving the Intended Effect

The O3 Sensor is noninvasively applied to the patient on one end. The other end of the O3 Sensor connects to the O3 Module. In turn, the O3 Module connects to a Host/Backboard device. The 03 Sensor collects patient physiological signals which are processed by the O3 Module. The processed signals which resulted in rSO2 measurements are displayed on the Host/Backboard device.

{7}------------------------------------------------

Image /page/7/Picture/0 description: The image shows the logo for Masimo Corporation. The logo consists of a red circle with a white checkmark inside, followed by the word "Masimo" in black, bold font. To the right of the word "Masimo" is the text "MASIMO CORPORATION" in gray, followed by the address "52 Discovery, Irvine, CA 92618" also in gray.

Summary of Technological Characteristics of Subject Device Compared to Predicate Device

Table 12.5
FEATUREMasimo O3 Regional Oximeter System(with O3 Pediatric Sensor)Masimo O3 Regional Oximeter System(with O3 Large Sensor)Somanetics Invos System(with Pediatric SomaSensor)
510(k) NumberPendingPredicate: K160526Predicate: K082327
General Information
Indications for Use (IFU)The noninvasive Masimo O3 RegionalOximeter System and accessories are intendedfor use as an adjunct monitor of absolute andtrended regional hemoglobin oxygensaturation of blood (rSO2) in the cerebralregion under the sensors. The Masimo O3Regional Oximeter System and accessories areindicated for use on adults ≥ 40 kg and onpediatrics ≥ 5 kg and < 40 kg in healthcareenvironments.The noninvasive Masimo O3 RegionalOximeter System and accessories are intendedfor use as an adjunct monitor of absolute andtrended regional hemoglobin oxygensaturation of blood (rSO2) in the cerebralregion under the sensors. The Masimo O3Regional Oximeter System and accessories areindicated for use on adults ≥ 40 kg inhealthcare environments.The noninvasive INVOS 5100C is intended for useas an adjunct monitor of regional hemoglobinoxygen saturation of blood in the brain or in othertissue beneath the sensor. It is intended for use inindividuals greater than 2.5 kg risk for reduced-flowor no-flow ischemic states.It is also intended for use as an adjunct trendmonitor of regional hemoglobin oxygen saturationof blood in the brain or in other tissue beneath thesensor in any individual. The clinical value of trenddata has not been demonstrated in disease states.The INVOS System should not be used as the solebasis for diagnosis or therapy.
Classification Regulation/Product CodeSame as K160526 and K08232721 CFR 870.2700/ MUD21 CFR 870.2700/ MUD
Principle of OperationSame as K160526The O3 System operating principle is based onmulti-distance diffuse reflectancespectroscopy. The device uses light toexamine a cross-section tissuemicrovasculature (a mixed bed of arterioles,capillaries and venules) and analyzes the lightreturned after having passed through thetissue. The spectroscopic analysis determinesconcentrations of hemoglobin in itsoxygenated and deoxygenated states.The Invos 5100C is a 2 wavelength, diffusereflectance spectroscopy system employing nearinfrared light to estimate the percentage ofhemoglobin saturated with oxygen in tissueunderneath the sensor. An adhesive sensorcontaining a light source and 2 photodiodes isapplied to the skin over the tissue of interest and thereturning light is analyzed for oxyhemoglobin anddeoxyhemoglobin light absorption. Absorptionsignals from the photodiode closer to the light

{8}------------------------------------------------

Image /page/8/Picture/0 description: The image shows the logo for Masimo Corporation. The logo consists of a red circle with a white checkmark inside, followed by the word "Masimo" in black, bold font. To the right of the logo is the text "MASIMO CORPORATION" in gray, followed by the address "52 Discovery, Irvine, CA 92618" also in gray.

Table 12.5
Masimo O3 Regional Oximeter SystemMasimo O3 Regional Oximeter SystemSomanetics Invos System
FEATURE(with O3 Pediatric Sensor)(with O3 Large Sensor)(with Pediatric SomaSensor)
510(k) NumberPendingPredicate: K160526Predicate: K082327
source are subtracted from those from the farther
photodiode where the returning photons penetrate
more deeply in the tissue.
Patient PopulationAdults $\u2265$ 40 kgPediatrics $\u2265$ 5 kg and < 40 kgAdults > 40 kgPediatrics < 40 kg
Measurement SiteSame as K160526 and K082327Cerebral region, foreheadCerebral region, forehead
Type of UseSame as K160526 and K082327Single patient useSingle patient use
SterilitySame as K160526 and K082327Supplied non-sterileSupplied non-sterile
Accuracy (ARMS) *
Absolute Accuracy5% for SavO2 of 45%-85%4% for SavO2 of 45%-85%N/A
Trending Accuracy3% for SavO2 of 45%-85%3% for SavO2 of 45%-85%1.6% SaO2 of 74%-100% (per K082327 SaO2 rangeis for adults)
Dimensions
System Compatibility
Monitoring SystemSame as K160526Root Monitoring System with O3 ModuleInvos System
Biocompatibility
MaterialsSame as K160526 and K082327Biocompatible, ISO-10993 compliantBiocompatible, ISO-10993 compliant
Mechanical
Overall Dimension2.6x1.1x0.1 inch2.9x1.5x0.1 inch3.0x1.5x0.1 inch
Weight0.18 oz0.20 oz0.2 oz
Environmental
Operating TemperatureSame as K1605265°C to 40°C16°C to 32°C
Storage TemperatureSame as K160526-40°C to 60°C-20°C to 45°C
HumiditySame as K16052615% to 90% non-condensing20% to 80%, non-condensing

* AMS accuracy is a statistical calculation of the difference between device measurements. Approximately wo-thirds of the device measurements fell within +/- ARMs of the reference measurements in a controlled study.

{9}------------------------------------------------

Image /page/9/Picture/0 description: The image shows the logo for Masimo Corporation. The logo consists of a red circle with a white checkmark inside, followed by the word "Masimo" in a bold, sans-serif font. To the right of the logo is the text "Masimo Corporation" in a smaller, lighter font, followed by the address "52 Discovery, Irvine, CA 92618".

Non-clinical Testing

The following tests, as applicable, were performed for the qualification of the subject devices, O3 System, in accordance with the requirements of the design control regulations and established quality assurance processes to demonstrate substantial equivalence with the predicate device:

  • Electrical safety testing per IEC-60601-1 ●
  • EMC testing per IEC-60601-1-2 ●
  • Alarm testing per IEC-60601-1-8
  • Optical safety testing per IEC-62471 ●
  • Biocompatibility testing per ISO-10993
  • . Usability testing per FDA Human Factors and Usability Draft Guidance
  • Software verification per FDA Software Guidance ●
  • Mechanical and environmental testing ●

The results demonstrate that all requirements and performance specifications were satisfied, and that the subject device is substantially equivalent to the predicate device.

Clinical Testing

In the study for Absolute ARMS, rSO2 measurements were collected using the O3 System, including the O3 Module (K160526) and O3 Pediatric Sensor, on 33 male and female pediatric patients with ages ranging from less than one year to 12 years. Blood draws (arterial and jugular blood) were taken for each subject before and after his/her medical procedure. The rSO2 measurements were analyzed against blood draw measurements and the Absolute ARMs were calculated in the same manner as in K160526.

As the O3 Large Sensor trending accuracy was established with blood reference via K160526, the O3 Large Sensor was used as a reference in the comparative trending study with the O3 Pediatric Sensor. The rSO2 data was collected for both O3 Large Sensor and O3 Pediatric Sensor. The relative rSO2 value between the O3 Large Sensor and O3 Pediatric Sensor was then calculated. The Trending ARMs for the O3 Pediatric Sensor was derived by taking the relative error between the O3 Large Sensor and O3 Pediatric Sensor into account.

{10}------------------------------------------------

Image /page/10/Picture/0 description: The image shows the logo for Masimo Corporation. The logo consists of a red circle with a white checkmark inside, followed by the word "Masimo" in black, bold letters. To the right of the logo is the text "MASIMO CORPORATION" in gray, followed by the address "52 Discovery, Irvine, CA 92618" also in gray.

Conclusion

The clinical evaluation, non-clinical testing including safety testing, as included in this 510(k) submission, demonstrate that the subject device, O3 Pediatric Sensor, is substantially equivalent to its predicate with respect to safety and effectiveness.

§ 870.2700 Oximeter.

(a)
Identification. An oximeter is a device used to transmit radiation at a known wavelength(s) through blood and to measure the blood oxygen saturation based on the amount of reflected or scattered radiation. It may be used alone or in conjunction with a fiberoptic oximeter catheter.(b)
Classification. Class II (performance standards).